Cartesian Therapeutics, Inc. (RNAC) Operating income 2016–2025
Cartesian Therapeutics, Inc. (RNAC) annual operating income history from SEC filings — each fiscal year as reported.
-$143.4MFY2025 · since FY2016: -$34.7M → -$143.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$143.4M | -226.7% |
| FY2024 | -$43.9M | +49.2% |
| FY2023 | -$86.4M | -694.4% |
| FY2022 | $14.5M | +416.2% |
| FY2021 | -$4.6M | +91.9% |
| FY2020 | -$56.8M | -8.3% |
| FY2019 | -$52.5M | +19.3% |
| FY2018 | -$65.0M | -1.9% |
| FY2017 | -$63.8M | -84.0% |
| FY2016 | -$34.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice